---
schema_version: "secwatch.filing_event.v1"
accession: "0001398733-26-000052"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2026-09-29T11:22:07+00:00"
generated_at: "2026-10-12T13:41:46.164571+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Aquestive Therapeutics elects Richard J. Daly to board, expanding directorships from seven to eight

## Summary
- Richard J. Daly elected as Class I director effective October 14, 2026, with term expiring at the 2028 Annual Meeting of Stockholders.
- Board size increased from seven to eight directors; seven of eight are independent under Nasdaq listing standards.
- Daly receives an initial award of 57,000 stock options under the 2018 Equity Incentive Plan, vesting in annual one-third increments.
- Option grant date is the second full trading day after the next quarterly or annual earnings release, with exercise price equal to that day's closing price.
- CEO Daniel Barber cited Daly's commercial leadership at AstraZeneca, Takeda and Catalyst as valuable for a potential Anaphylm launch.

## SEC filing metadata
- accession: 0001398733-26-000052
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2026-09-29T11:22:07+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000052/0001398733-26-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000052/aqst-20260929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001398733-26-000052
- JSON: https://secwatch.observer/filing/0001398733-26-000052.json
- Plain text: https://secwatch.observer/filing/0001398733-26-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.